In Brief: Damon Labs indictments
This article was originally published in The Gray Sheet
Executive Summary
Damon Labs indictments: Justice Department indicts four former executives of Damon Clinical Laboratories on charges that they conspired to defraud Medicare of "over $25 mil.," according to a Jan. 22 release from the Office of the U.S. Attorney General. Charged are Joseph Isola, Beno Kon, William Thurston and Gerald Kullen. The indictment alleges that the four individuals were involved in a scheme while at Damon to defraud Medicare by adding the infrequently ordered serum ferritin test to a commonly ordered panel of blood chemistry tests, and the apolipoproteins test to a coronary risk profile panel. The indictment also charges that Isola, Kon and Thurston manipulated physician practice by dividing a common test panel for end-stage renal disease patients into two separate panels for which samples were taken on different days. In October 1996, Damon pleaded guilty to conspiracy to defraud Medicare and paid criminal and civil fines totaling $119 mil...
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.